J. Pons

发表

Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements.

Mark M. Davis, D. Koller, K. Roskin, 2014, Cell host & microbe.

Impact of mutations on the allosteric conformational equilibrium.

A. Sali, Yao Chi Chen, J. Pons, 2013, Journal of molecular biology.

Structure-based model of allostery predicts coupling between distant sites

Andrej Sali, A. Sali, J. Pons, 2012, Proceedings of the National Academy of Sciences.

Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism

Wei Ye, Vazgen Khankaldyyan, W. Ye, 2004, Laboratory Investigation.

Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire

Jan Berka, Jacob Glanville, Arvind Rajpal, 2009, Proceedings of the National Academy of Sciences.

Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation

Stephen L. Hauser, Jorge R. Oksenberg, Jan Berka, 2011, Proceedings of the National Academy of Sciences.

The Restricted DH Gene Reading Frame Usage in the Expressed Human Antibody Repertoire Is Selected Based upon its Amino Acid Content

Yoram Louzoun, Jacob Glanville, Lea Tsaban, 2013, The Journal of Immunology.

RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

M. Dorywalska, A. Rajpal, J. Pons, 2016, Molecular Cancer Therapeutics.

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

M. Dorywalska, J. Chaparro-Riggers, A. Rajpal, 2013, Chemistry & biology.

Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies.

C. Craik, J. Pons, Charles S Craik, 2003, Biochemistry.

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

Amy Y. Chen, J. Pons, S. Kauder, 2018, PloS one.

Expanding the ProteOn XPR36 biosensor into a 36-ligand array expedites protein interaction analysis.

A. Rajpal, J. Pons, Y. Abdiche, 2011, Analytical biochemistry.

Anti-GD2 antibody disrupts GD2:Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication

Rachel E. Brewer, I. Weissman, P. Sorensen, 2021, bioRxiv.

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Rachel E. Brewer, I. Weissman, M. Monje, 2022, Nature Medicine.

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease.

J. Pons, K. Bales, T. Kawabe, 2012, Journal of molecular biology.

Deglycosylated Anti-Aβ Antibody Dose–Response Effects on Pathology and Memory in APP Transgenic Mice

J. Grimm, J. Pons, D. Morgan, 2008, Journal of Neuroimmune Pharmacology.

Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum

A. Rajpal, J. Pons, Y. Abdiche, 2013, PloS one.

Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates.

Rachel M. Devay, A. Rajpal, J. Pons, 2017, Bioconjugate chemistry.

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

M. Dorywalska, A. Rajpal, J. Pons, 2016, Molecular Cancer Therapeutics.

Effect of attachment site on stability of cleavable antibody drug conjugates.

M. Dorywalska, A. Rajpal, J. Pons, 2015, Bioconjugate chemistry.

Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy

M. Dorywalska, A. Rajpal, J. Pons, 2015, PloS one.

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

M. Dorywalska, A. Rajpal, J. Pons, 2015, Nature Biotechnology.

Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates.

M. Dorywalska, A. Rajpal, J. Pons, 2014, Bioconjugate chemistry.

Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis

J. Pons, A. Rosenthal, D. Shelton, 2005, Pain.

Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions

A. Rajpal, J. Pons, Y. Abdiche, 2012, PloS one.

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2&Dgr;a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

C. Baum, J. Pons, B. Gumbiner, 2018, Cardiovascular therapeutics.

High-Throughput Epitope Binning Assays on Label-Free Array-Based Biosensors Can Yield Exquisite Epitope Discrimination That Facilitates the Selection of Monoclonal Antibodies with Functional Activity

A. Rajpal, J. Pons, Y. A. Yeung, 2014, PloS one.

The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity

J. Chaparro-Riggers, A. Rajpal, J. Pons, 2015, mAbs.

Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma

J. Pons, Jordi Martínez, J. Besalduch, 2006, Leukemia & lymphoma.

Label-free epitope binning assays of monoclonal antibodies enable the identification of antigen heterogeneity.

A. Rajpal, J. Pons, Y. Abdiche, 2012, Journal of immunological methods.

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

Amy Y. Chen, J. Pons, D. Fontaine, 2020, Journal of Hematology & Oncology.

A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2019, Blood.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet.

J. Pons, Y. Abdiche, Jaume Pons, 2008, Analytical biochemistry.

Successful chemotherapy including epirubicin in a pregnant non-Hodgkin's lymphoma patient.

J. Pons, F. Goldwasser, J. Cosset, 1995, Leukemia & lymphoma.

Direct control of CAR T cells through small molecule-regulated antibodies

Xiaodi A Deng, J. Chaparro-Riggers, J. Pons, 2021, Nature Communications.

Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice

J. Pons, D. Morgan, M. Gordon, 2009, The Journal of Neuroscience.

Introduction: Antibody Structure and Function

J. Chaparro-Riggers, A. Rajpal, J. Pons, 2013 .

Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration

Sina Farsiu, Bing Kuang, Catherine Bowes Rickman, 2011, Proceedings of the National Academy of Sciences.

Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.

Pavel Strop, Arvind Rajpal, J. Chaparro-Riggers, 2012, Journal of molecular biology.

Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9*

Rachel M. Devay, J. Chaparro-Riggers, A. Rajpal, 2012, The Journal of Biological Chemistry.

Germline-encoded neutralization of a Staphylococcus aureus virulence factor by the human antibody repertoire

M. Sirota, Xiaodi A Deng, J. Glanville, 2016, Nature Communications.

A method for integrative structure determination of protein-protein complexes

Hong Liang, Andrej Sali, Dina Schneidman-Duhovny, 2012, Bioinform..

A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.

P. LoRusso, J. Pons, W. Messersmith, 2018 .

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

Amy Y. Chen, A. Madan, J. Pons, 2019, mAbs.

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

Phenotype-information-phenotype cycle for deconvolution of combinatorial antibody libraries selected against complex systems

Ali Torkamani, Richard A Lerner, Hongkai Zhang, 2011, Proceedings of the National Academy of Sciences.

Production of soluble and active microbial transglutaminase in Escherichia coli for site‐specific antibody drug conjugation

A. Rajpal, J. Pons, P. Strop, 2016, Protein science : a publication of the Protein Society.

Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus α-hemolysin.

A. Rajpal, J. Pons, P. Strop, 2013, Journal of molecular biology.

1 Introduction : Antibody Structure and Function

J. Chaparro-Riggers, A. Rajpal, J. Pons, 2013 .

Synthetic antibodies designed on natural sequence landscapes.

D. Cox, M. Fuhrmann, J. Glanville, 2011, Journal of molecular biology.

Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies

Marina Sirota, Shobha Potluri, Arvind Rajpal, 2017, mAbs.

Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02)

G. Garcia-Manero, J. Pons, J. Altman, 2021, Blood.

Intracranial administration of deglycosylated C-terminal-specific antiA β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

Jan Grimm, Dave Morgan, J. Grimm, 2015 .

39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period.

J. Pons, John C. Lin, Nancy Raha, 2012, Journal of Alzheimer's disease : JAD.

Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencing.

Jan Berka, Pavel Strop, Arvind Rajpal, 2015, Journal of molecular biology.

Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates

J. Chaparro-Riggers, A. Rajpal, J. Pons, 2012, Journal of Pharmacology and Experimental Therapeutics.

Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti‐NGF monoclonal antibody, using a repertoire of biosensors

J. Pons, Y. Abdiche, Dan S Malashock, 2008, Protein science : a publication of the Protein Society.

Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain*

A. Crameri, A. Rajpal, J. Pons, 2016, The Journal of Biological Chemistry.

ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

J. Pons, P. Squifflet, W. Kim, 2020 .

Identification of Novel Small-Molecule Inhibitors for Human Transketolase by High-Throughput Screening with Fluorescent Intensity (FLINT) Assay

J. Pons, Zheng Yin, L. Fang, 2004, Journal of biomolecular screening.

The uptake of a Klebsiella pneumoniae capsule polysaccharide mutant triggers an inflammatory response by human airway epithelial cells.

J. Pons, V. Regueiro, J. Bengoechea, 2006, Microbiology.

Deglycosylated Anti-Amyloid-β Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice

J. Grimm, D. Wilcock, J. Pons, 2006, The Journal of Neuroscience.

Abstract 13322: The Effects of Single Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects Treated with and without Atorvastatin

C. Baum, J. Pons, B. Gumbiner, 2012 .

Abstract 13524: The Effects of Multiple Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects

C. Baum, J. Pons, B. Gumbiner, 2012 .

Exploring blocking assays using Octet, ProteOn, and Biacore biosensors.

J. Pons, Y. Abdiche, Jaume Pons, 2009, Analytical biochemistry.

Epitope Mapping Using Yeast Display and Next Generation Sequencing.

J. Berka, J. Chaparro-Riggers, A. Rajpal, 2018, Methods in molecular biology.

Intracranial administration of deglycosylated C-terminal-specific antiA β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice

J. Grimm, D. Wilcock, J. Pons, 2015 .

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

Amy Y. Chen, J. Pons, S. Kauder, 2018, PloS one.

39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period.

J. Pons, John C. Lin, Nancy Raha, 2012, Journal of Alzheimer's disease : JAD.

Generation of a high-fidelity antibody against nerve growth factor using library scanning mutagenesis and validation with structures of the initial and optimized Fab-antigen complexes

M. Ultsch, C. Eigenbrot, J. Pons, 2014, mAbs.

498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01

Y. Bang, J. Pons, P. Squifflet, 2021, Journal for ImmunoTherapy of Cancer.

Impact of mutations on the allosteric conformational equilibrium.

A. Sali, Yao Chi Chen, J. Pons, 2013, Journal of molecular biology.